---
title: diagnostic evaluation
date: "2023-01-22"
enableToc: false
---

> [!info]
>
> ðŸŒ± ä¾†è‡ª: [[acute leukemia]]

# diagnostic evaluationÂ 

(BloodÂ 2009;114:937)

*Â **Peripheral smear:**Â thrombocytopenia,Â **blasts**Â (seen in >95%; âŠ• Auer Rods in AML)

*Â **Bone marrow:**Â >20% blasts; mostly hypercellular; test for cytogenetics and flow cytometry for immunophenotype (AML/ALL)

*Â **Cytogenetic anomalies**: eg, in AML, t(15;17), t(8;21), inv(16) or t(16;16), complex; in ALL, Ph-chromosome [t(9;22)], hyper or hypodiploid, complex

* Molecular mutations in AML: espÂ _FLT3_Â (ITD and TKD),Â _TP53, NPM1;_Â ALL_: BCR-ABL1_

* Evaluate for complications: TLS (â†‘ uric acid, â†‘ LDH, â†‘ K, â†‘ PO4, â†“ Ca), DIC (PT, PTT, fibrinogen, D-dimer, haptoglobin, bilirubin), check for G6PD (prior to giving rasburicase)

* LP (w/Â **co-admin of intrathecal chemotherapy**Â to avoid seeding CSF w/ circulating blasts) for all Pts w/ ALL (CNS is sanctuary site) and for Pts w/ AML w/ CNS sx

* TTE before use of anthracyclines

*Â **[[HLA typing]]**Â of Pt, siblings >parents/children for potential allogeneic HSCT candidates

